Related Experiment Video
Updated: Mar 17, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Life-Time Risk, Screening and The Cost of Cardiovascular Comorbidities in CKD Patients
Insights
Chronic kidney disease (CKD) poses a significant public health risk, comparable to heart attacks. Addressing the economic impact of CKD-related cardiovascular issues is crucial for effective prevention strategies.
Area of Science:
- Nephrology
- Cardiology
- Public Health
- Health Economics
Background:
- Chronic kidney disease (CKD) is a widespread health issue with epidemic proportions.
- CKD patients face a mortality and cardiovascular complication risk equivalent to myocardial infarction.
- The economic burden of cardiovascular comorbidities in CKD patients is substantial.
Purpose of the Study:
- To highlight the significant economic impact of cardiovascular comorbidities in CKD patients.
- To emphasize the need for cost-effectiveness studies on preventive interventions for CKD.
- To call for research into reducing CKD risk and associated cardiovascular complications.
Main Methods:
- Epidemiological data analysis from the MONICA-Augsburg study.
- Cost analysis of myocardial infarction from a German health insurance company.
Main Results:
- Cardiovascular comorbidities in CKD patients represent a substantial economic burden in Germany.
- CKD is a "risk equivalent" for death and cardiovascular complications compared to myocardial infarction.
Conclusions:
- The substantial economic burden of CKD-related cardiovascular issues necessitates further investigation.
- Cost-effectiveness studies of preventive interventions are crucial for managing CKD and its complications.
- Findings may be applicable to other large European Union member states.
Abstract:
CKD is a problem of epidemic dimension. The risk of death and cardiovascular complications in this condition is of the same order of that by myocardial infarction, which qualifies CKD as "risk equivalent". Calculations made on the basis of the epidemiological data of the MONICA-Augsburg study and analyses of the costs of myocardial infarction in a large health insurance company in Germany show that the economic burden of cardiovascular comorbidities with CKD in this country is substantial. These estimates, which may be valid also for other large member states of the European Community, represent a call for studies looking at the cost-effectiveness of preventive interventions aimed at reducing the risk for CKD and at lowering the concerning incidence rate of death and disability due to CKD-triggered cardiovascular complications in CKD patients.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Heart Failure Drugs: Diuretics
Acute Kidney Injury III: Clinical Manifestations

